Survey of Rejection Prophylaxis Following Suture Removal in Penetrating Keratoplasty in Germany

Abstract

Background Penetrating keratoplasty (PK) gets more and more reserved to cases of increasing complexity. In such cases, ocular comorbidities may limit graft survival following PK. A major cause for graft failure is endothelial graft rejection. Suture removal is a known risk factor for graft rejection. Nevertheless, there is no evidence-based regimen for rejection prophylaxis following suture removal. Therefore, a survey of rejection prophylaxis was conducted at 7 German keratoplasty centres.

Objective The aim of the study was documentation of the variability of medicinal aftercare following suture removal in Germany.

Methods Seven German keratoplasty centres with the highest numbers for PK were selected. The centres were sent a survey consisting of half-open questions. The centres performed a mean of 140 PK in 2018. The return rate was 100%. The findings were tabulated.

Results All centres perform a double-running cross-stitch suture for standard PK, as well as a treatment for rejection prophylaxis with topical steroids after suture removal. There are differences in intensity (1 – 5 times daily) and tapering (2 – 20 weeks) of the topical steroids following suture removal. Two centres additionally use systemic steroids for a few days.

Discussion Rejection prophylaxis following PK is currently poorly standardised and not evidence-based. All included centres perform medical aftercare following suture removal. It is assumed that different treatment strategies show different cost-benefit ratios. In the face of the diversity, a systematic analysis is required to develop an optimised regimen for all patients.

Key words

keratoplasty - rejection - prophylaxis - suture - removal

Publikationsverlauf

Eingereicht: 19. November 2020

Angenommen: 28. Dezember 2020

Artikel online veröffentlicht:
25. Februar 2021

• References/Literatur

• 1 Tan DTH, Dart JKG, Holland EJ. et al. Corneal transplantation. Lancet 2012; 379: 1749-1761 doi:10.1016/S0140-6736(12)60437-1
• 2 Daniel MC, Böhringer D, Lapp T. et al. [Keratoplasty in Germany: Systematic Analysis of the Quality Reports of German Hospitals between 2006 and 2017]. Klin Monbl Augenheilkd 2020; DOI: 10.1055/a-1035-9442.
• 3 Flockerzi E, Maier P, Böhringer D. et al. Trends in Corneal Transplantation from 2001 to 2016 in Germany: A Report of the DOG-Section Cornea and its Keratoplasty Registry. Am J Ophthalmol 2018; 188: 91-98 doi:10.1016/j.ajo.2018.01.018
• 4 Randleman JB, Stulting RD. Prevention and treatment of corneal graft rejection: current practice patterns (2004). Cornea 2006; 25: 286-290 doi:10.1097/01.ico.0000178731.42187.46
• 5 Patel NP, Kim T, Rapuano CJ. et al. Indications for and outcomes of repeat penetrating keratoplasty, 1989–1995. Ophthalmology 2000; 107: 719-724
• 6 Di Zazzo A, Kheirkhah A, Abud TB. et al. Management of high-risk corneal transplantation. Surv Ophthalmol 2017; 62: 816-827 doi:10.1016/j.survophthal.2016.12.010
• 7 Williams KA, Lowe M, Bartlett C. et al. Risk Factors for Human Corneal Graft Failure Within the Australian Corneal Graft Registry. Transplantation 2008; 86: 1720-1724 doi:10.1097/TP.0b013e3181903b0a
• 8 Böhringer D, Schwartzkopff J, Maier PC. et al. [HLA matching in keratoplasty: lessons learned from lamellar techniques]. Klin Monbl Augenheilkd 2013; 230: 490-493 doi:10.1055/s-0032-1328256
• 9 Böhringer D, Grotejohann B, Ihorst G. et al. Rejection Prophylaxis in Corneal Transplant. Dtsch Arztebl Int 2018; 115: 259-265 doi:10.3238/arztebl.2018.0259
• 10 Molter Y, Milioti G, Langenbucher A. et al. [Appearance, recurrence and prognosis of immunological graft rejection after penetrating keratoplasty]. Ophthalmologe 2020; 117: 548-556 doi:10.1007/s00347-019-00975-9
• 11 Thompson RW, Price MO, Bowers PJ. et al. Long-term graft survival after penetrating keratoplasty. Ophthalmology 2003; 110: 1396-1402 doi:10.1016/S0161-6420(03)00463-9
• 12 Coster DJ, Williams KA. The impact of corneal allograft rejection on the long-term outcome of corneal transplantation. Am J Ophthalmol 2005; 140: 1112-1122 doi:10.1016/j.ajo.2005.07.024
• 13 Sibley D, Hopkinson CL, Tuft SJ. et al. Differential effects of primary disease and corneal vascularisation on corneal transplant rejection and survival. Br J Ophthalmol 2020; 104: 729-734 doi:10.1136/bjophthalmol-2019-314200
• 14 Crawford AZ, Meyer JJ, Patel DV. et al. Complications related to sutures following penetrating and deep anterior lamellar keratoplasty. Clin Exp Ophthalmol 2016; 44: 142-143 doi:10.1111/ceo.12635
• 15 Jonas JB, Rank RM, Budde WM. Immunologic graft reactions after allogenic penetrating keratoplasty. Am J Ophthalmol 2002; 133: 437-443
• 16 Sharif KW, Casey TA. Penetrating keratoplasty for keratoconus: complications and long-term success. Br J Ophthalmol 1991; 75: 142-146
• 17 Leahey AB, Avery RL, Gottsch JD. et al. Suture abscesses after penetrating keratoplasty. Cornea 1993; 12: 489-492
• 18 Wertheim MS, Keel M, Cook SD. et al. Corneal transplant rejection following influenza vaccination. Br J Ophthalmol 2006; 90: 925 doi:10.1136/bjo.2006.093187
• 19 Böhringer D, Sundmacher R, Reinhard T. [Suture complications in penetrating keratoplasty]. Klin Monbl Augenheilkd 2010; 227: 735-738 doi:10.1055/s-0028-1110005
• 20 Azevedo Magalhaes O, Shalaby Bardan A, Zarei-Ghanavati M. et al. Literature review and suggested protocol for prevention and treatment of corneal graft rejection. Eye (Lond) 2020; 34: 442-450 doi:10.1038/s41433-019-0517-9
• 21 Sun XT, Zhai HL, Cheng J. et al. Indications for penetrating keratoplasty and anterior lamellar keratoplasty during 2010–2017. Int J Ophthalmol 2019; 12: 1878-1884 doi:10.18240/ijo.2019.12.10
• 22 Ayalew M, Tilahun Y, Holsclaw D. et al. Penetrating Keratoplasty at a Tertiary Referral Center in Ethiopia: Indications and Outcomes. Cornea 2017; 36: 665-668 doi:10.1097/ICO.0000000000001190
• 23 Al-Yousuf N, Mavrikakis I, Mavrikakis E. et al. Penetrating keratoplasty: indications over a 10 year period. Br J Ophthalmol 2004; 88: 998-1001 doi:10.1136/bjo.2003.031948
• 24 Feilmeier MR, Tabin GC, Williams L. et al. The use of glycerol-preserved corneas in the developing world. Middle East Afr J Ophthalmol 2010; 17: 38-43 doi:10.4103/0974-9233.61215
• 25 Hoffmann F. [Suture technique for perforating keratoplasty (authorʼs transl)]. Klin Monbl Augenheilkd 1976; 169: 584-590
• 26 Wacker K, Reinhard T. [Immunosuppression after corneal transplantation: Clinical standards and novel approaches]. Ophthalmologe 2016; 113: 432-434 doi:10.1007/s00347-016-0268-y
• 27 Abudou M, Wu T, Evans JR. et al. Immunosuppressants for the prophylaxis of corneal graft rejection after penetrating keratoplasty. Cochrane Database Syst Rev 2015; (08) CD007603 DOI: 10.1002/14651858.CD007603.pub2.
• 28 Nguyen NX, Seitz B, Martus P. et al. Long-term topical steroid treatment improves graft survival following normal-risk penetrating keratoplasty. Am J Ophthalmol 2007; 144: 318-319 doi:10.1016/j.ajo.2007.03.028
• 29 Shimazaki J, Iseda A, Satake Y. et al. Efficacy and safety of long-term corticosteroid eye drops after penetrating keratoplasty: a prospective, randomized, clinical trial. Ophthalmology 2012; 119: 668-673 doi:10.1016/j.ophtha.2011.10.016
• 30 Tabbara KF. Pharmacologic strategies in the prevention and treatment of corneal transplant rejection. Int Ophthalmol 2008; 28: 223-232 doi:10.1007/s10792-007-9100-7
• 31 Reinhard T, Mayweg S, Reis A. et al. Topical FK506 as immunoprophylaxis after allogeneic penetrating normal-risk keratoplasty: a randomized clinical pilot study. Transpl Int 2005; 18: 193-197 doi:10.1111/j.1432-2277.2004.00006.x
• 32 Reinhard T, Reis A, Böhringer D. et al. Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 yearsʼ results of a randomized prospective clinical trial. Graefes Arch Clin Exp Ophthalmol 2001; 239: 367-372
• 33 Behrens A, Seitz B, Langenbucher A. et al. Lens opacities after nonmechanical versus mechanical corneal trephination for keratoplasty in keratoconus. J Cataract Refract Surg 2000; 26: 1605-1611 doi:10.1016/s0886-3350(00)00717-3
• 34 Mayweg S, Reinhard T, Spelsberg H. et al. [Ranking of systemic steroids after normal-risk keratoplasty. Results of a randomized prospective study]. Ophthalmologe 2005; 102: 497-501 doi:10.1007/s00347-004-1148-4
• 35 Fu H, Larkin DFP, George AJT. Immune modulation in corneal transplantation. Transplant Rev (Orlando) 2008; 22: 105-115 doi:10.1016/j.trre.2007.12.005
• 36 Lapp T, Maier P, Birnbaum F. et al. [Immunosuppressives to prevent rejection reactions after allogeneic corneal transplantation]. Ophthalmologe 2014; 111: 270-282 doi:10.1007/s00347-013-3016-6
• 37 Wacker K, Denker S, Hildebrand A. et al. Short-Term Azithromycin Treatment Promotes Cornea Allograft Survival in the Rat. PLoS One 2013; 8: e82687 doi:10.1371/journal.pone.0082687
• 38 Medina CA, Rowe AM, Yun H. et al. Azithromycin treatment increases survival of high-risk corneal allotransplants. Cornea 2013; 32: 658-666 doi:10.1097/ICO.0b013e318274a690
• 39 Kagkelaris KA, Makri OE, Georgakopoulos CD. et al. An eye for azithromycin: review of the literature. Ther Adv Ophthalmol 2018; 10: 2515841418783622 doi:10.1177/2515841418783622